目的 评价中国科学院合肥肿瘤医院新型抗肿瘤药的临床使用情况和用药趋势，为促进临床合理用药提供依据。方法 采用回顾性的方法分析2018-2022年中国科学院合肥肿瘤医院临床使用的新型抗肿瘤药的消耗量、销售金额、用药频度（DDDs）、限定日费用（DDC）及药品销售金额排序（B）/DDDs排序（A）情况。结果 2018-2022年，医院新型抗肿瘤药物的品种数和销售金额呈逐年增长趋势，品种数从2018年的11种增加到2022年的49种，销售金额从2018年的270.34万元增长至2022年的2 543.00万元。2018-2019年，甲磺酸阿帕替尼片的销售金额及其DDDs排序均居第1位；2020-2021年，注射用卡瑞利珠单抗的销售金额排序居第1位，其DDDs 2021年居第1位。2022年，贝伐珠单抗注射液的销售金额排序居第1位，其DDDs排序居第3位。吉非替尼片销售金额不断下降，但其DDDs在2018-2021年均居前3位。2018-2022年，中国科学院合肥肿瘤医院大部分新型抗肿瘤药各品种的DDC处于逐年降低趋势。2020年卡瑞利珠单抗B/A<1，患者经济负担较重，2021年入围国家医保谈判品种后，价格大幅度下降，B/A达到1，2022年B/A>1；重组人血管内皮抑制素、贝伐珠单抗的B/A均<1，可能与其近年来销售金额增加有关；厄洛替尼、埃克替尼的B/A均>1，说明其价格更低、使用频率更高，大部分药品的DDC相对稳定，B/A接近于1，提示其销售金额与DDDs的同步性总体较好。结论 中国科学院合肥肿瘤医院新型抗肿瘤药的临床使用相对合理，需要加强抗肿瘤药物临床应用管理，建立相关考核指标体系并纳入绩效考核，从而确保临床使用新型抗肿瘤药物安全、有效、经济。

Objective To evaluate the clinical use and drug use trend of new anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences, so as to provide a basis for promoting clinical rational drug use. Methods Using a retrospective method, the consumption, sales amount, DDDs, DDC, and B/A of new anti-tumor drugs used in Hefei Cancer Hospital, Chinese Academy of Sciences were statistically analyzed from 2018 to 2022. Results From 2018 to 2022, the variety and sales amount of new anti-tumor drugs in hospital increased year by year. The number of varieties increased from 11 in 2018 to 49 in 2021, and the sales amount increased from 2.703 4 million yuan in 2018 to 25.43 million yuan in 2022. From 2018 to 2019, the sales value and its DDDs of Apatinib Mesylate Tablets ranked first. From 2020 to 2021, the sales amount of Camrelizumab for injection ranked first, and its DDDs ranked first in 2021. In 2022, the sales amount of Bevacizumab Injection ranked first, and its DDDs ranked third. The sales amount of Gefitinib Tablets continues to decline, but its DDDs ranks among the top 3 from 2018 to 2021. From 2018 to 2022, the DDC of most of the new anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences was decreasing year by year. In 2020, the B/A of camrelizumab is far less than 1, indicating that patient's economic burden is heavy. After entering the national medical insurance negotiation category in 2021, the price dropped significantly, and B/A reached 1, and B/A > 1 in 2022. B/A of recombinant human endostatin and bevacizumab were all lower than 1, which may be related to the increase in sales amount in recent years. The B/A of erlotinib and icotinib were all > 1, indicating that their prices were lower and their use frequency was higher. The DDC of most drugs was relatively stable, and B/A was close to 1, indicating that the synchronization between their sales sum and DDDs was generally good. Conclusion The clinical use of new anti-tumor drugs in Hefei Cancer Hospital, Chinese Academy of Sciences is relatively reasonable, and it is necessary to strengthen the clinical application management of anti tumor drugs, establish the relevant assessment index system and incorporate it into the performance assessment, so as to ensure the safety, effectiveness and economy of clinical use of new anti-tumor drugs.

R979.1